<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Observational studies suggest that <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) reduce the risk of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, but it is not known at what stage they may act in the <z:mp ids='MP_0003278'>esophageal inflammation</z:mp>-<z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence </plain></SENT>
<SENT sid="1" pm="."><plain>In an <z:hpo ids='HP_0000001'>all</z:hpo>-Ireland case-control study, we investigated the relationship between the use of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and risk of reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, long-segment <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and population controls were recruited from throughout Ireland </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0100633'>Esophagitis</z:hpo> patients were recruited from Northern Ireland only </plain></SENT>
<SENT sid="4" pm="."><plain>Data were collected on known and potential risk factors for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and on the use of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi>, including aspirin, at least 1 year before interview </plain></SENT>
<SENT sid="5" pm="."><plain>Associations between use of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and the stages of the <z:mp ids='MP_0003278'>esophageal inflammation</z:mp>-<z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence were estimated by multiple logistic regression </plain></SENT>
<SENT sid="6" pm="."><plain>In total, 230 reflux <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, 224 <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and 227 esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and 260 population controls were recruited </plain></SENT>
<SENT sid="7" pm="."><plain>Use of aspirin and <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> was associated with a reduced risk of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> [odds ratio [OR; 95% confidence interval (95% CI)], 0.53 (0.31-0.90) and 0.40 (0.19-0.81), respectively] and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> [OR (95% CI), 0.57 (0.36-0.93) and 0.58 (0.31-1.08), respectively] </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> patients were less likely than controls to have used <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Selection or recall bias may explain these results and the results of previous observational studies indicating a protective effect of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> against esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>If <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> have a true protective effect on the <z:mp ids='MP_0003278'>esophageal inflammation</z:mp>-<z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> sequence, they may act early in the sequence </plain></SENT>
</text></document>